Autopsy report · NCT00206440

Nexium Study To Suppress Nausea During Chemotherapy

“Accrual was not optimized”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 6 years 6 months before it stopped.
• 43 participants enrolled.
• Results were posted on the registry 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Baylor Breast Care Center

Sponsor type

University, hospital or other

Conditions

Nausea

Interventions

esomeprazole; Placebo

Participants

43

Sites

1

Countries

United States

Trials that died the same way

• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (77% match in meaning)
• CD8 Reactivity to Microorganisms in Blood and Breast Milk
  “Slow/insufficient accrual” (77% match in meaning)
• Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
  “Low accrual; target accrual not met” (75% match in meaning)
• Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
  “Insufficient accrual” (75% match in meaning)
• Dry Needling for Shoulder Adhesive Capsulitis
  “Poor Accrual” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.